Tesamorelin

Human evidence can mean a controlled clinical study, an observational study, a safety or exposure report, or evidence from a particular finished formulation. Those are different kinds of information.

Human evidence in specific contexts. Human studies are available in defined contexts, but the evidence remains product-, population-, route-, or outcome-specific.

Preclinical means research in cells, tissues, or animals rather than in people. It can help researchers form a hypothesis, but it cannot establish a human benefit or a complete human safety profile.

Nonclinical studies informed carcinogenicity, reproductive, and pharmacology assessments. Growth-hormone and IGF-1 pathway effects do not establish benefit outside the labeled population.[1]

Preclinical findings do not establish outcomes in people.

Risk information may describe the compound, a finished product, a route, a population, or product-quality concerns. The cited material does not replace a current product label or an individual professional assessment.

This section is about the United States only. Status applies to a product, formulation, route, population, and use—not to a name in the abstract. A status shown here is not a recommendation or a statement about another country.

• Source/status dateJan 2, 2026

  FDA-approved medicine

  Tesamorelin is FDA approved as Egrifta products to reduce excess abdominal fat in adults with HIV and lipodystrophy. It is not labeled for general weight-loss management.

  Specific product form or route is not separately published in this status record.

  Open source context

The date above is the date attached to the published status record or source context. It is not necessarily the original approval date.

These prompts help organise a conversation with a qualified professional. They do not create a treatment recommendation, dose, or protocol.

• EvidenceWhich human evidence applies to the exact product, form, route, and use being discussed?
• What remains uncertainWhat is known, and what remains uncertain for this specific context?
• RisksWhich important warnings, common effects, and product-quality concerns should be discussed?
• U.S. statusWhat does the U.S. status cover, and what does it not cover?

Related means that the profiles share a topic, pathway, product context, or research question. It does not mean that they are equivalent.

• SomatropinTesamorelin and somatropin affect the growth-hormone axis through different mechanisms and approvals.

PeptideGrid review date: Jul 22, 2026. Sources support the specific sections that cite them. Publication does not imply endorsement, equivalence, or individual suitability.

1. 1

   EGRIFTA SV prescribing information

   DailyMed. EGRIFTA SV (tesamorelin) prescribing information. Revised January 2026.

   National Library of Medicine / Theratechnologies · Published Jan 2, 2026 · Accessed Jul 22, 2026 · Prescribing information

   Open source